Navigation Links
CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
Date:9/23/2009

VIENNA, Va., Sept. 23 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines and therapeutics for the treatment of infectious diseases and a late-stage oncology company, announced today that it has hired a full-service Clinical Research Organization (CRO) with an office in the Washington, D.C./Baltimore area to support its conduct of the upcoming clinical trial of its investigational LEAPS-H1N1 treatment. Last week, CEL-SCI announced that the U.S. Food and Drug Administration (FDA) had indicated that the Company can proceed with its first clinical trial to evaluate the effect of its investigational LEAPS-H1N1 treatment on the white blood cells of hospitalized H1N1 patients. This followed the very responsive and expedited initial review of CEL-SCI's regulatory submission for this study proposal by the FDA. Following completion of manufacturing, initiation of this first study is subject to IRB review and approval. The study will involve taking blood from hospitalized, laboratory-confirmed H1N1 patients and activating their cells with the LEAPS-H1N1 investigational therapy in order to assess the cells' response as the basis for the planned future treatment of this patient population under a next-stage clinical trial protocol.

In order for FDA to fully consider that next-stage clinical trial to evaluate LEAPS-H1N1 treatment of hospitalized patients with laboratory-confirmed H1N1 Pandemic Flu under an Exploratory IND, FDA has asked CEL-SCI to submit a detailed follow-up regulatory filing with extensive additional data. Thus, in parallel with ramping up its first study, CEL-SCI is proceeding on an expedited basis with the substantial undertaking necessary to complete this next submission. Recognizing that it cannot proceed with its next-stage clinical trial without the Agency
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... 29, 2015 , ... Healthpointe, one of Southern California’s leading ... MD., PhD into their world-class multidisciplinary team of physicians and specialists. Dr. ... Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of Healthpointe, such as ...
(Date:6/29/2015)... ... 2015 , ... Mediaplanet has released the first edition of ... 12-page, glossy, full-color special section hit newsstands Friday, June 26th, and was distributed ... copies, with an estimated readership of 1.3 million. The digital component is being ...
(Date:6/29/2015)... NEW YORK, NEW YORK (PRWEB) , ... June ... ... obstructive sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. ... and Drug Administration and is an alternative to continuous positive airway pressure (CPAP), ...
(Date:6/29/2015)... ... 2015 , ... National HealthCare Associates recently released a list ... 40-center nursing home group. Sixteen of their centers were rated “Best in Class” ... one or more customer service areas. Those centers received the prestigious “Customer Experience ...
(Date:6/29/2015)... ... 2015 , ... With Urgent Care Medicine now serving a vital role in ... Urgent Care Medicine and the Medical Society of Delaware to provide its latest professional ... health care professionals. , According to Matthew Bader, Exam Master CEO and President, “This ...
Breaking Medicine News(10 mins):Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 2Health News:Exam Master Partners to Provide New Urgent Care Continuing Medical Education Resource 3
... , HARBIN, China, Sept. 9 ... CKGT), a vertically integrated grower,developer, manufacturer and marketer of ... the Rodman and Renshaw Annual Global Investment,Conference to be ... Kangtai,Cactus Biotech will present as part of the Asia ...
... , , Obesity Experts ... , SILVER SPRING, Md., Sept. 9 ... to Overcome and Prevent (STOP) Obesity Alliance, and two former US Surgeons ... act on the inclusion of obesity as the largest and most urgent ...
... , CAMBRIDGE, Mass., Sept. 9 ... enterprise content compliance software solutions for ... Software-as-a-Service (SaaS) solution for managing clinical trial disclosure requirements. The ... a robust offering that automates compliance with global regulatory mandates ...
... , , TARRYTOWN, N.Y., Sept. 9 Bayer ... (R) 2 blood glucose meters -- Pink and Purple. , ... same unique easy to use(1) features as the original silver BREEZE2 ... the meter itself, so users do not have to handle individual ...
... They can get variety of illnesses from the sexually transmitted ... A U.S. health advisory committee on Wednesday will discuss whether ... transmitted human papillomavirus (HPV), for use in boys as well ... has asked the U.S. Food and Drug Administration to approve ...
... , , TITUSVILLE, ... to impact up to 20 percent of children(1) and 4 percent ... underdiagnosed: researchers estimate up to 20 percent of U.S. school-aged children ... but only 7.8 percent report receiving an ADHD diagnosis.(3) Meanwhile, it ...
Cached Medicine News:Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 2Health News:China Kangtai Cactus Biotech to Present at the Rodman & Renshaw Annual Global Investment Conference in New York on September 11, 2009 3Health News:Obesity Driving America's Healthcare to a Tipping Point 2Health News:Obesity Driving America's Healthcare to a Tipping Point 3Health News:Obesity Driving America's Healthcare to a Tipping Point 4Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 2Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 3Health News:Virtify Delivers SaaS Clinical Trial Disclosure Solution for Mid-Market Life Sciences Companies 4Health News:Bayer's BREEZE(R)2 Meter Available in Two New Vibrant Colors for a Limited Time 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 2Health News:FDA Panel Weighs Approving HPV Vaccine for Males 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 2Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 3Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 4Health News:CONCERTA(R) (methylphenidate HCI) LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 5
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: